Latest Commercial Partnerships News

Sparc Technologies has secured a $680,000 non-dilutive advance on its anticipated FY26 R&D tax refund, strengthening its cash flow as it accelerates commercialisation of its graphene additive ecosparc and green hydrogen ventures.

Nanoveu Limited showcased its cutting-edge EMASS semiconductor technology at the Pitt Street Research Semiconductor Conference 2026, spotlighting its ultra-low-power AI chips designed for next-gen smart devices and drones.

Sparc Technologies has formalised a collaboration with HydroGraph Clean Power to test and potentially commercialise graphene-enhanced additives for protective coatings, aiming to revolutionise corrosion protection.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Lynas Rare Earths and Japan Australia Rare Earths B.V. have extended their supply agreement to 2038, securing firm commitments for critical rare earths with a pricing floor and upside sharing mechanism.

Audeara Limited has initiated three new white-label Auracast™ programs with Clinico Inc., alongside launching its BT-03 Audio Broadcaster in Australia, marking a significant step in scaling its audio technology globally.

Nimy Resources has addressed a recent spike in its share price and trading volume, attributing the movement to its Managing Director's U.S. trade mission and the release of a commissioned research article.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Merino & Co. Limited reported a 60.5% drop in revenue and a 28.2% increase in net loss for the half-year ending December 2025, reflecting a strategic investment phase aimed at future growth. The company is expanding production capacity and building inventory ahead of wholesale expansion, signaling a pivot towards revenue acceleration.

Brisbane Broncos Limited has reported a robust 2025 financial year, with profit before tax soaring 35% to $11.34 million, buoyed by premiership wins in both the NRL and NRLW competitions. The club also declared a special dividend, reflecting its strong commercial and community momentum.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

BluGlass Limited reported a 14% revenue increase to A$5.76 million and a 28% reduction in net loss to A$4.1 million for H1 FY26, bolstered by a key US Department of War contract extension and a refreshed board driving growth.